Academic Study Finds TB Alliance’s Access Approach Successfully Accelerated Uptake of New TB Treatments

24 April 2026

TB Alliance news release

A new peer-reviewed study led by the Geneva Graduate Institute finds that TB Alliance’s approach to expanding access to new treatments for drug-resistant TB (DR-TB) has been highly effective, demonstrating how coordinated, nonprofit-led efforts can rapidly translate scientific innovation into real-world impact on people affected by TB.

Published in BMJ Global Health, the study examines how access to pretomanid and the BPaL/M regimens, developed by TB Alliance, expanded at an unprecedented speed. These newer regimens shorten DR-TB treatment, reduce the burden on people and health systems, and improve treatment outcomes. By 2024, more than 100 countries had ordered pretomanid in volumes sufficient to meet approximately 63% of global demand — just two years after the World Health Organization recommended the BPaL/M regimens for the treatment of most forms of DR-TB. This represented a significantly faster pace than had typically been seen in global health, where access to new innovations historically took 7-9 years to scale broadly.

Read the full news release here.

Source: TB Alliance